Skip to content

A Phase I, Single-blind, Randomized Study of the Safety and Efficacy of Cellularized Integra® Using Autologous Burn-derived Stem Cells

A Phase I, Single-blind, Randomized Study of the Safety and Efficacy of Cellularized Integra® Using Autologous Burn-derived Stem Cells

Status
Not yet recruiting
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05344521
Acronym
Integra®-SC
Enrollment
29
Registered
2022-04-25
Start date
2024-02-29
Completion date
2027-02-28
Last updated
2023-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burns

Keywords

Stem Cells, Wound Healing, Cicatrix, Skin, Artificial

Brief summary

Burn injuries are one of the most severe skin injuries and lead to a complex wound healing response. When the skin is wounded, stem cells in the skin must respond fast to help repair the injured tissue. The damaged skin of burn patients contains cells that are still alive and have typical stem cell characteristics. Because stem cells are so important for wound healing, the investigators have combined them with an existing skin substitute, Integra®, to examine the potential wound healing benefits of these stem cells. This is an investigational treatment and a first in-human trial. The purpose of this study is to test the safety of using a patient's own stem cells combined with Integra®, which the investigators call Integra®-Stem Cells (Integra®-SC). The investigators hypothesize that Integra®-SC will result in improved wound healing, better scar quality, and decreased scar formation at one-year post-injury.

Interventions

DEVICEIntegra®

A commercially available dermal bovine matrix that is widely used for wound and burn care, Integra® Dermal Regeneration Template licensed device (Medical Device Active License Listing No. 229).

DEVICEIntegra®-SC

A combination of Integra® incorporated with 5,000-20,000 cells/cm2 of autologous burned derived stem cells.

Sponsors

AFP Innovation Fund
CollaboratorOTHER
Ontario Institute for Regenerative Medicine
CollaboratorUNKNOWN
Stem Cell Network
CollaboratorOTHER
Hamilton Health Sciences Corporation
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

This is a single-blind study where the participant will not know which area is covered with Integra®-SC.

Intervention model description

Integra®-SC will be applied to one area of the body and acellular Integra® will be applied to another. Determination of the location of the Integra® control or Integra®-SC application will be assigned using simple randomization. The wound areas will be appropriately matched for body surface area and depth of the wound.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged ≥ 18 years. * Total body surface area (TBSA) ≥ 5%. * Full-thickness burn requiring operative procedures. * Admitted ≤ 120 hours following burn. * Injury location includes a contralateral area.

Exclusion criteria

All participants meeting any of the following

Design outcomes

Primary

MeasureTime frameDescription
Safety - Number of participants with surgical site infectionsAcute hospitalization (1-4 months post admission depending on severity of injury)The primary outcome of this study is safety. In order to assess the safety of Integra®-SC, surgical site infections that require an additional (unplanned) operation will be recorded as an in-hospital complication.
Safety - Number of participants with non-healing woundsAcute hospitalization (1-4 months post admission depending on severity of injury)The primary outcome of this study is safety. In order to assess the safety of Integra®-SC, non-healing wounds that require an additional (unplanned) operation will be recorded as an in-hospital complication.
Safety - Number of patients with poor scarring requiring additional (unplanned) operationDischarge to to 1 year post-dischargeThe primary outcome of this study is safety. In order to assess the safety of Integra®-SC, poor scarring requiring an additional (unplanned) operation will be recorded as a late-onset complication.

Secondary

MeasureTime frameDescription
Quality of skin regeneration - Detachment of Integra®-SCAcute hospitalization (1-4 months post admission depending on severity of injury)The detachment of the entire Integra®-SC from the wound site will be recorded to assess the quality of skin regeneration. Photography and evaluation of wounds will occur at enrollment, operation days, dressing take-downs, and discharge from hospital.
Quality of skin regeneration - Abnormal scar formationAcute hospitalization (1-4 months post admission depending on severity of injury)The formation of hypertrophic scars or keloids will be recorded to assess the quality of skin regeneration. Photography and evaluation of wounds will occur at enrollment, operation days, dressing take-downs, and discharge from hospital.
Scar Formation - Vascularity of the healed areaDischarge to 1 year post-dischargeVascularity of the healed area is assessed as part of the Vancouver Scar Scale to evaluate scar formation over time. Vascularity is scored from 0 to 3, with higher scores indicating worse outcomes. Photography and evaluation of treated area for scar formation will be assessed at outpatient follow-ups at approximately 30 days, 60 days, 90 days, 180 days, and 365 days post-discharge (with 2-4 weeks deviation). Follow-ups typically take place in-person at clinic visits, but may take place online via a secure platform.
Time of wound healingAcute hospitalization (1-4 months post admission depending on severity of injury)Time from wound excision to 95% healing of the burned area will be recorded. Photography and evaluation of wounds will occur at enrollment, operation days, dressing take-downs, and discharge from hospital.
Scar formation - Pliability of the healed areaDischarge to 1 year post-dischargePliability of the healed area is assessed as part of the Vancouver Scar Scale to evaluate scar formation over time. Pliability is scored from 0 to 5, with higher scores indicating worse outcomes. Photography and evaluation of treated area for scar formation will be assessed at outpatient follow-ups at approximately 30 days, 60 days, 90 days, 180 days, and 365 days post-discharge (with 2-4 weeks deviation). Follow-ups typically take place in-person at clinic visits, but may take place online via a secure platform.
Scar formation - Height of the healed areaDischarge to 1 year post-dischargeThe height of the healed area is assessed as part of the Vancouver Scar Scale to evaluate scar formation over time. Height is scored from 0 to 3, with higher scores indicating worse outcomes. Photography and evaluation of treated area for scar formation will be assessed at outpatient follow-ups at approximately 30 days, 60 days, 90 days, 180 days, and 365 days post-discharge (with 2-4 weeks deviation). Follow-ups typically take place in-person at clinic visits, but may take place online via a secure platform.
Scar formation - Pigmentation of the healed areaDischarge to 1 year post-dischargePigmentation of the healed area is assessed as part of the Vancouver Scar Scale to evaluate scar formation over time. Pigmentation is scored from 0 to 2, with higher scores indicating worse outcomes. Photography and evaluation of treated area for scar formation will be assessed at outpatient follow-ups at approximately 30 days, 60 days, 90 days, 180 days, and 365 days post-discharge (with 2-4 weeks deviation). Follow-ups typically take place in-person at clinic visits, but may take place online via a secure platform.
Quality of skin regeneration - Arterial bleeding from the wound siteAcute hospitalization (1-4 months post admission depending on severity of injury)Arterial bleeding from the wound site will be recorded to assess the quality of skin regeneration. Photography and evaluation of wounds will occur at enrollment, operation days, dressing take-downs, and discharge from hospital.
Quality of skin regeneration - Signs of wound infectionAcute hospitalization (1-4 months post admission depending on severity of injury)Classic signs of wound infection will be recorded to assess the quality of skin regeneration. Photography and evaluation of wounds will occur at enrollment, operation days, dressing take-downs, and discharge from hospital.

Countries

Canada

Contacts

Primary ContactMarc G Jeschke, MD PhD
marc.jeschke@hhsc.ca905-521-2100

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026